Author Guidelines, Criteria & Review Charter
Standardized submission criteria for proffered research papers, late-breaking clinical trials, and scientific poster exhibitions at ADC-RadCon 2027. All proffered manuscripts are subjected to blinded collegiate review under the Declaration of Helsinki research charter.
Technical Specifications & Structural Requirements
Proffered abstracts must adhere strictly to these core technical parameters to qualify for intake and reviewer assignment.
Length & Word Limits
Strict limit of 350 words excluding title, track code, and section headings. Submissions exceeding this threshold are returned automatically for revision prior to editorial review.
Double-Blind Anonymization
Author names, institutional affiliations, hospital departments, and geographical identifiers must be excluded from the abstract body and title text to protect evaluation impartiality.
Track & Taxonomy Assignment
Authors must select one primary track (Track 01–05) and corresponding subtopic code (e.g., TC-03.1 for Actinium Chelation) to ensure assignment to the appropriate specialist review panel.
Mandatory Four-Heading Abstract Anatomy
| Required Heading | Content Scope & Empirical Focus | Target Length |
|---|---|---|
| 1. Background & Aim | Articulates the clinical or translational bottleneck, specific oncological target, hypothesis, and objective of the investigational conjugate or radioligand. | ~50–70 Words |
| 2. Methods & Chemistries | Synthetic bio-conjugation protocols, chelator synthesis, linker-payload architectures, analytical assays (LC-MS, HPLC, RCP/RCY), cell line models, or clinical trial designs. | ~80–110 Words |
| 3. Results & Data | Empirical metrics: IC50 values, radiochemical purity (RCP), in vitro plasma stability, in vivo rodent biodistribution, or quantitative RECIST/PERCIST patient response rates. | ~110–140 Words |
| 4. Conclusions & Impact | Translational significance, therapeutic index widening, impact on hospital bedside practices, and ongoing or proposed Phase I–III trial directions. | ~40–60 Words |
Declaration of Helsinki & Data Integrity Protocols
The review directorate enforces rigorous research ethics standards for all laboratory, animal, and clinical patient investigations.
Clinical Trials & Patient Imaging Data
Submissions detailing patient-derived data, theranostic imaging (PET/SPECT), or biopsy analytics must confirm:
- Institutional Review Board (IRB) Clearance: Active protocol authorization from an accredited medical ethics committee or institutional review board.
- Declaration of Helsinki Compliance: Adherence to the ethical principles governing medical research involving human subjects.
- Patient De-Identification: Complete stripping of patient names, dates of birth, hospital numbers, and MRN codes from all datasets and figures.
- Trial Registration: Provision of ClinicalTrials.gov or EudraCT trial identifier numbers where applicable.
Preclinical Radiochemistry & Animal Studies
Submissions involving rodent models, in vitro payload assays, or radioisotope handling must confirm:
- IACUC Approval: Compliance with institutional animal care and use committee standards for in vivo imaging and biodistribution.
- Radiochemical Yield & Purity: Explicit disclosure of radiochemical yield (RCY) and purity (RCP > 95%) with specified analytical validation methods.
- Commercial Firewalls: Research funded by commercial sponsors must report unbiased analytical comparisons using non-proprietary chemical nomenclatures.
- Conflict of Interest (COI): Mandatory disclosure of commercial funding, equity, or patent ownership during the submission intake process.
Commercial Content Prohibition: Abstracts containing overt promotional language, proprietary marketing claims without underlying chemical disclosure, or vendor product brochures will be rejected at initial editorial screening prior to peer review.
Peer-Review Evaluation Matrix & Scoring Criteria
Reviewers score each anonymized abstract across four distinct weighted domains on a scale of 1 to 100.
Scientific Rigor & Data Completeness
Evaluation of statistical validity, experimental controls, analytical verification (HPLC, LC-MS), and robustness of preliminary findings.
Translational Novelty
Originality of the linker chemistry, innovative radioisotope chelation cages, or novel combination paradigms in treatment-refractory tumors.
Clinical Utility & Impact
Direct applicability to current oncology challenges, widening the therapeutic window, or addressing radioisotope supply bottlenecks.
Clarity & Presentation
Adherence to structural headings, concise data presentation, correct chemical/radiological terminology, and English fluency.
Accepted Presentation Allocation Categories
Based on reviewer scores and thematic fit, accepted abstracts are assigned to one of three official presentation categories.
Plenary Oral Podium Defense
Assigned to top-ranked manuscripts. Includes a 15-minute podium presentation (10-minute slide defense followed by 5 minutes of moderated audience discussion) in Hall Alpha or Beta.
Moderated Poster Exhibition
Assigned to high-scoring empirical studies. Includes a dedicated display board in the central exhibition concourse and structured participation in the morning faculty poster walks.
Virtual E-Poster Presentation
Allocated for overseas investigators registered under the Virtual Technical Pass. Includes digital e-poster hosting on the conference portal and inclusion in the indexed proceedings volume.